ESMO 2020 Expert Video Report on precision medicine in prostate cancer
Reporting from the ESMO Virtual Congress 2020, Maria De Santis comments on promising therapeutic options and practice changing results presented in metastatic castration-resistant prostate cancer (mCRPC).
She emphasises the importance of testing CRPC patients for genomic alterations (BRCA1, BRCA2 or ATM) as soon as the cancer metastasises, to identify those who could benefit from targeted treatment options.
Abstracts:
- LBA4 - IPATential150: efficacy and safety from the Phase III study of ipatasertib plus abiraterone-prednisone (AP) vs placebo plus AP in metastatic castrate-resistant prostate cancer (mCRPC)
- 610O - Final overall survival (OS) analysis of PROfound: olaparib vs physician’s choice of enzalutamide or abiraterone in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations
Produced by ESMO, https://oncologypro.esmo.org
This video was supported with an educational grant from Janssen Pharmaceutical companies of Johnson & Johnson
Видео ESMO 2020 Expert Video Report on precision medicine in prostate cancer канала European Society for Medical Oncology
She emphasises the importance of testing CRPC patients for genomic alterations (BRCA1, BRCA2 or ATM) as soon as the cancer metastasises, to identify those who could benefit from targeted treatment options.
Abstracts:
- LBA4 - IPATential150: efficacy and safety from the Phase III study of ipatasertib plus abiraterone-prednisone (AP) vs placebo plus AP in metastatic castrate-resistant prostate cancer (mCRPC)
- 610O - Final overall survival (OS) analysis of PROfound: olaparib vs physician’s choice of enzalutamide or abiraterone in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations
Produced by ESMO, https://oncologypro.esmo.org
This video was supported with an educational grant from Janssen Pharmaceutical companies of Johnson & Johnson
Видео ESMO 2020 Expert Video Report on precision medicine in prostate cancer канала European Society for Medical Oncology
Показать
Комментарии отсутствуют
Информация о видео
1 октября 2020 г. 0:46:12
00:08:51
Другие видео канала
![ESMO 2020 Expert Video Report on CDK4 6i in the adjuvant treatment of breast cancer](https://i.ytimg.com/vi/MEOSI9DXe7o/default.jpg)
![ESMO 2019 Expert Video Report on Prostate Cancer](https://i.ytimg.com/vi/LI8KtIRuVeo/default.jpg)
![Next generation of ALK TKI inhibitors for treatment of advanced ALK-positive NSCLC](https://i.ytimg.com/vi/BPtm63O-kGc/default.jpg)
![Post ASCO Webinar](https://i.ytimg.com/vi/emKDKnz7PqY/default.jpg)
![Precision Medicine When Every Cancer IS Personal | Adam Marcus | TEDxPeachtree](https://i.ytimg.com/vi/LgntY0dOf_c/default.jpg)
![ESMO 2020 Expert Video Report on the combination of immuno and targeted therapies in melanoma](https://i.ytimg.com/vi/8IoZyNKVTP4/default.jpg)
![ESMO 2020 Expert Video Report on rare sarcomas histotypes](https://i.ytimg.com/vi/0uo1Abc-t8s/default.jpg)
![Tumori con fusione NTRK e GMI, che novità da ESMO 2020? L’esempio di larotrectinib](https://i.ytimg.com/vi/blBrYiVRMRg/default.jpg)
![ESMO 2020 Highlights on blocking PI3K/AKT signalling pathway in mCRPC: The IPATential150 study](https://i.ytimg.com/vi/3bO9bW3Uir0/default.jpg)
![ESMO 2019 Expert Video Report on ovarian cancer](https://i.ytimg.com/vi/ueU6JtPfvGY/default.jpg)
![The use of abiraterone and enzalutamide against CRPC](https://i.ytimg.com/vi/QYZ5eISjIkY/default.jpg)
![ESMO 2020 Expert Video Report on long term ICI outcomes in lung cancer](https://i.ytimg.com/vi/fMg4Z1fSDr4/default.jpg)
![Melanoma Highlights from ASCO 2020](https://i.ytimg.com/vi/7zGpJbtOH-c/default.jpg)
![ESMO 2019 Expert Video Report on Carcinoma of Unknown Primary](https://i.ytimg.com/vi/rIArXoopzFI/default.jpg)
![ESMO Daily Reporter Talk: The role of CDK4/6 inhibitors in the early stage of #breastcancer.](https://i.ytimg.com/vi/3FnHxkk2jnk/default.jpg)
![Expert video report on Melanoma from AACR 2020](https://i.ytimg.com/vi/cgc7TirLF0M/default.jpg)
![ESMO 2020 Expert Video report on atezolizumab in upfront treatment of TNBC](https://i.ytimg.com/vi/tpACwFD2qWg/default.jpg)
![ESMO 2020 Highlights on 1st line durvalumab and tremelimumab for mPDAC: The PA.7 study](https://i.ytimg.com/vi/i4_TpJ3_crY/default.jpg)
![How to use endocrine therapy in premenopausal women with ER+ early breast cancer](https://i.ytimg.com/vi/y4tIqk9b2uQ/default.jpg)
![ESMO Expert video report on urothelial cancer from ASCO 2020](https://i.ytimg.com/vi/1tw-UrxMeCM/default.jpg)